{
    "Symbol": "AZN",
    "AssetType": "Common Stock",
    "Name": "AstraZeneca PLC ADR",
    "Description": "AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.",
    "CIK": "901832",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, GB",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-06-30",
    "MarketCapitalization": "251763835000",
    "EBITDA": "16973000000",
    "PERatio": "39.42",
    "PEGRatio": "0.886",
    "BookValue": "25.49",
    "DividendPerShare": "2.97",
    "DividendYield": "0.0183",
    "EPS": "2.06",
    "RevenuePerShareTTM": "2.633",
    "ProfitMargin": "0.131",
    "OperatingMarginTTM": "0.224",
    "ReturnOnAssetsTTM": "0.0768",
    "ReturnOnEquityTTM": "0.167",
    "RevenueTTM": "49132999000",
    "GrossProfitTTM": "35732000000",
    "DilutedEPSTTM": "2.06",
    "QuarterlyEarningsGrowthYOY": "0.06",
    "QuarterlyRevenueGrowthYOY": "0.133",
    "AnalystTargetPrice": "90.07",
    "AnalystRatingStrongBuy": "4",
    "AnalystRatingBuy": "7",
    "AnalystRatingHold": "1",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "39.42",
    "ForwardPE": "16.31",
    "PriceToSalesRatioTTM": "4.665",
    "PriceToBookRatio": "5.46",
    "EVToRevenue": "5.2",
    "EVToEBITDA": "17.74",
    "Beta": "0.15",
    "52WeekHigh": "82.01",
    "52WeekLow": "59.55",
    "50DayMovingAverage": "78.66",
    "200DayMovingAverage": "70.02",
    "SharesOutstanding": "3100540000",
    "DividendDate": "2024-09-09",
    "ExDividendDate": "2024-08-09"
}